May 20, 2021 / 04:40PM GMT
Phil Nadeau - Cowen and Company - Analyst
Good afternoon and welcome once again to Cowen and Company's 2nd Annual Oncology Innovation Summit. I'm Phil Nadeau, one of the biotech analysts here at Cowen, and it's my pleasure to moderate the session with Atara Biotherapeutics.
I'm very happy to have with us today Pascal Touchon, the President and CEO; and AJ Joshi, the CMO.
Questions and Answers:
Phil Nadeau - Cowen and Company - AnalystFirst, I believe we'll start with Tab-cel. On your recent earnings call, you provided meaningful updates on the ALLELE trial as well as the status of your BLA. Could you briefly review those for us?
Pascal Touchon - Atara Biotherapeutics, Inc. - President, CEO
Yes, certainly. AJ, do you want to start about the ALLELE trial and then I will talk about the BLA status?
AJ Joshi - Atara Biotherapeutics, Inc. - CMO
Sure. So, the update that we provided was primarily around a recent review of the data. Remember, what we had discussed
Trustpilot
